The main Wolverine peptide news through October 2026 is that pairing BPC-157 and TB-500 still shows no proven advantage over single peptides. New animal and human reports arrived this quarter, while an October FDA peptide notice entered federal review. None of those updates proved that combining the two peptides improves human recovery.
In telehealth clinics, Wolverine usually means a two-peptide blend of BPC-157 and TB-500. In September headlines, however, researchers and reporters used the phrase Wolverine peptide for BPC-157 alone. Keeping those two meanings straight helps make sense of this quarter's research.
Wolverine prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Standalone BPC-157 and TB-500 are also not FDA-approved.
Changelog: July to October 2026
October 14, 2026 — The FDA sent an interim peptide compounding notice for federal review. As of October 17, 2026, the day this article was written, a White House review log listed this pending filing. Titled "Interim Access Policy for Compounding Using Certain Peptides" (RIN 0910-ZD94), the entry names no specific peptides and changes nothing today.
September 30, 2026 — A Frontiers in Oral Health case report described three patients given BPC-157 and TB-500 after lower-jaw nerve injuries. Each patient also received another peptide, a steroid, and local anesthetics without a control group. Because several treatments were used together, the report cannot show whether the peptide pair helped.
September 21, 2026 — The World Anti-Doping Agency 2027 announcement confirmed that the 2027 Prohibited List takes effect on January 1, 2027. It keeps BPC-157 in category S0 and TB-500 under S2.3. WADA prohibits both peptides at all times, in and out of competition, just as on the 2026 Prohibited List.
September 15, 2026 — A syndicated Reuters report covered the September 7 preprint on rising BPC-157 chart mentions. The article noted that the true scale of BPC-157 use remains unknown.
September 7, 2026 — A non-peer-reviewed Preprints.org chart-note study used the label Wolverine Peptide for BPC-157 alone, as covered in BPC-157 real-world use. Among 1,039 documented BPC-157 users, 134 patients (12.9%, or about 1 in 8) also had TB-500 in their charts.
August 24, 2026 — Five FDA warning letters cited unapproved injectable drugs sold online; none named BPC-157, TB-500, or a Wolverine blend.
A prescribed route includes a clinician responsible for the prescribing decision and follow-up, plus an identified licensed U.S. dispensing pharmacy. It also provides a way to report a suspected adverse reaction. A gray-market checkout without a prescription skips that clinical review. Those process differences do not establish the effectiveness or long-term safety of a peptide blend.
August 11, 2026 — A scoping review in the American Journal of Sports Medicine found that 67% of studies across six peptides (about two-thirds) used animal models. Its abstract concluded that proposed sports-medicine benefits remain unsubstantiated by human trials.
July 23, 2026 — At the July 23–24 Pharmacy Compounding Advisory Committee meeting, advisers reviewed free base and acetate forms of BPC-157 and TB-500. As covered in our FDA peptide decision guide, committee recommendations are non-binding and did not evaluate a combined blend.
July 23, 2026 — A study in Joint Diseases and Related Surgery tested BPC-157, TB-500, and their combination on Achilles tendon repair in 32 rats.
What October 2026 Wolverine peptide news shows about the pair
The main question behind a two-peptide blend is whether two ingredients work better together than one alone. A July rat tendon study directly tested that question and found no statistically significant added benefit from the combination.
In that July 23 experiment, researchers cut and repaired the Achilles tendon in 32 male rats. They split the animals into four equal groups of eight for 30 days. Researchers then tested four tendons per group for breaking strength and four under a microscope for tissue healing.
| Study group (8 rats each; 4 tendons tested for strength) | Median load before tendon failure | Statistically significant vs. untreated control? |
|---|---|---|
| Untreated control | 26.91 N | Baseline group |
| BPC-157 alone | 37.16 N | Not significant after adjustment |
| TB-500 alone | 37.41 N | Yes (p = 0.0406) |
| BPC-157 + TB-500 combined | 34.54 N | Not significant after adjustment |
Only TB-500 alone cleared the statistical bar against the untreated control group after adjustment. Each strength test used only four tendons per group, and the paper did not report the exact TB-500 sequence. Those limits mean this small animal study cannot prove how the pair works in people.
Human data on the pairing remain limited to uncontrolled reports. As of October 17, 2026, the day this article was written, ClinicalTrials.gov and PubMed searches showed no controlled human trial isolating the pair.
That does not mean no person has ever received both peptides. Three patients in the September 30 dental report received both peptides alongside other drugs. The September 7 chart-note preprint also found 134 patients (about 1 in 8 BPC-157 users) with TB-500 co-use.
Neither report tested a standardized two-ingredient blend against a comparison group. Without a control group, those records cannot show that combining the peptides improves recovery.
Standing facts: what is in the blend and where FDA review stands
As covered in our overview of the Wolverine peptide stack, the blend pairs two synthetic peptides studied mainly in animal models. BPC-157 is a 15-amino-acid chain. A May 2026 FDA staff evaluation noted that its molecular targets remain unidentified and its mechanisms are poorly understood.
A separate May 2026 FDA evaluation reviewed TB-500 as a seven-amino-acid fragment (Ac-LKKTETQ) of the larger 43-amino-acid protein thymosin beta-4. The agency noted that suppliers sometimes use the name TB-500 for different chemical sequences. Because of that naming mix-up, studies of the full protein do not automatically apply to the short fragment.
On the FDA compounding safety page, BPC-157 and the thymosin-beta-4 fragment appear under withdrawn nominations rather than Category 2. The May FDA reviews cited limited human safety data and noted that BPC-157 may pose a significant risk for immunogenicity (an unwanted immune reaction).
The BPC-157 review also noted one voluntary report of darkened skin and gums after a dual-labeled product. Spontaneous reports cannot establish that the product or either ingredient caused the event. Our guide to Wolverine peptide side effects covers those safety unknowns in detail.
Neither ingredient appears on the FDA 503A bulk drug substances categories list updated May 14, 2026. Under Section 503A compounding rules, adding an ingredient to the final bulks list requires formal notice-and-comment rulemaking. A Federal Register search through October 17, 2026 found no matching rule after July. On October 28, 2026, HHS filed the resulting peptide policy for Federal Register publication; our explainer sets out which peptides it names and its conditions.
Because neither peptide has a commercial drug label, any compounded version is different from an FDA-approved medication and is not FDA-approved. Regulatory status is one part of the visit, and a licensed provider may still prescribe — that decision is between you and your doctor.
Weighing the blend against a single peptide
When you discuss Wolverine with a clinician, the visit covers your condition, existing care, current medicines, and past reactions. A provider also weighs whether combining two unapproved peptides makes sense when no human trial shows the pair beats one ingredient.
Taking two peptides in one formulation creates a practical trade-off if a new side effect appears. Neither you nor your doctor can easily tell whether BPC-157 or TB-500 caused the reaction. Using a single ingredient is not proven safer or more effective, but it makes tracking your response simpler.
For patients who want to discuss a single-peptide option today, Promise offers BPC-157 on its own. Standalone TB-500 is coming soon to Promise as a compounded medication, different from an FDA-approved product: the formulation Promise will offer is not FDA-approved.
Competitive athletes face an additional rule whether they use the blend or a single peptide. WADA prohibits both BPC-157 and TB-500 at all times, both in and out of competition. Holding a prescription does not clear a tested athlete without a formal Therapeutic Use Exemption.
At Promise, a licensed provider reviews every request, and not everyone qualifies. When a clinician writes a prescription, Wolverine prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy. Your prescribing provider sets the treatment plan and follow-up schedule.
